UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Mind Medicine (MindMed) Inc.

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead ...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., ...

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23.

纽约 - 专注于开发脑健康疾病治疗方法的生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)被选入纳斯达克生物技术指数 (NBI)。该公司将于2024年12月23日开盘时正式纳入指数。目前，该公司市值约5.3亿美元，根据 InvestingPro 分析，其财务健康状况获得FAIR评级。

Bio-Techne Corporation , a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the ...

Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

"MindMed doses first subject in trial of tablets for generalised anxiety disorder" was originally created and published by ...

FREE! Biopharma firm Mind Medicine announced that they have dosed the first-ever patient in a Phase 3 clinical trial of ...

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...